Known or likely PTEN alterations were identified in 27.2% of prostate cancer profiles.20 The most common predictive markers in urothelial carcinoma were TMB ≥ 10 mut/Mb (34.6%), which may inform treatment with immune checkpoint inhibitors, and sensitizing alterations in FGFR2 or FGFR3 (17.3%), as specified in the label of the approved FGFR tyrosine kinase inhibitor erdafitinib (Table 3).21 This evidence concerns the gene FGFR3 and prostate carcinoma.